TREM-1通路生物标志物用于牙周病分类及B级和C级牙周炎治疗反应监测
本研究纳入牙龈炎、III期牙周炎(B级和C级)及健康对照,检测唾液TREM-1、PGLYRP1和IL-1β的诊断价值及预测治疗结局的能力。结果显示所有标志物可区分牙周炎与健康(AUC≥0.9),TREM-1可区分牙周炎与牙龈炎(AUC=0.72),但基线水平不能预测治疗结局(AUC≤0.61)。结论认为唾液TREM-1通路标志物具有诊断价值,受治疗调节,但预测治疗结局能力有限。
要点
- 唾液TREM-1、PGLYRP1和IL-1β区分牙周炎与健康AUC≥0.9,灵敏度82.1%-92.8%,特异度83.3%-88.9%。
- TREM-1区分牙周炎与牙龈炎AUC=0.72,灵敏度92.8%,特异度58.1%。
- 基线标志物不能预测治疗结局(AUC≤0.61),T1水平显示中等潜力(AUC≥0.71)。
核心结论
- 唾液TREM-1通路生物标志物对牙周炎具有诊断价值,受治疗调节,但预测治疗结局的能力有限。
研究设计与样本
- 招募全身健康非吸烟者:牙龈炎31例、III期牙周炎(B级34例、C级24例)及健康对照34例。
- 牙周炎患者42例接受非手术牙周治疗,基线(T0)及治疗后(T1、T3、T6)采集唾液。
- 采用免疫测定法检测生物标志物,根据T6时探诊出血且残留牙周袋≥5 mm的数量将患者分为应答者19例和无应答者23例。
主要发现
- TREM-1在牙周炎中高于牙龈炎和健康,牙周炎B级高于牙龈炎(p < 0.05)。
- PGLYRP1和IL-1β在牙周炎和牙龈炎中均高于对照(p < 0.01)。
- 所有标志物区分牙周炎与健康AUC≥0.9,灵敏度82.1%-92.8%,特异度83.3%-88.9%。
- TREM-1区分牙周炎与牙龈炎AUC=0.72,灵敏度92.8%,特异度58.1%。
- 基线标志物不能预测治疗结局(AUC≤0.61),T1水平显示中等潜力(AUC≥0.71)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study investigated the diagnostic potential of salivary triggering receptor expressed on myeloid cells (TREM)-1, peptidoglycan recognition protein 1 (PGLYRP1) and interleukin (IL)-1β for periodontitis patients and their ability to predict treatment outcome. METHODS: Systemically healthy, non-smokers with gingivitis (n = 31), stage III periodontitis (34 grade B: n = 34, grade C: n = 24) and healthy controls (n = 34) were recruited. Periodontitis patients (n = 42) underwent non-surgical periodontal treatment. Saliva was collected at baseline (T0) and post-treatment (T1, T3, T6). Biomarkers were measured using immunoassays. Periodontitis patients were categorised into responders (n = 19) and non-responders (n = 23) based on the number of residual pockets ≥ 5 mm with bleeding on probing at T6. RESULTS: TREM-1 was higher in periodontitis than in gingivitis and health, and in periodontitis grade B than in gingivitis (p < 0.05). PGLYRP1 and IL-1β were higher in periodontitis and gingivitis compared to controls (p < 0.01). All biomarkers discriminated periodontitis from health (AUC ≥ 0.9) with high sensitivity (82.1%-92.8%) and specificity (83.3%-88.9%). TREM-1 differentiated periodontitis from gingivitis (AUC = 0.72) with high sensitivity (92.8%) but low specificity (58.1%). Baseline biomarkers did not predict treatment outcome (AUC ≤ 0.61), while T1 levels showed moderate potential (AUC ≥ 0.71). CONCLUSIONS: Salivary TREM-1 pathway biomarkers offer diagnostic value for periodontitis, are modulated by therapy but show limited ability to predict treatment outcome. STUDY REGISTRATION: The study has been registered in ClinicalTrials.gov (ID: NCT06715176, 4 December 2024).
引用
- Silbereisen A, Lira-Junior R, Afacan B, et al. TREM-1 Pathway Biomarkers for Classification of Periodontal Diseases and Monitoring of Treatment Response in Grade B and C Periodontitis. J Clin Periodontol. 2025. PMID: 40528650. doi:10.1111/jcpe.14195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。